Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has appointed Australian contract research organisation Beyond ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Lung cancer continues to have a profound impact on many communities, but the disparity is especially notable within Black populations. In these communities, lung cancer incidence and mortality rates ...

Lung cancer has been widely perceived as a disease that predominantly affects men. However, recent epidemiological data indicate that it is increasingly being diagnosed in women. In fact, a large ...

Most people associate lung cancer primarily with smoking, but growing evidence suggests diet plays a more significant role than previously thought. While numerous foods help protect against cancer, ...